Efficacy and safety of mirikizumab in maintenance therapy for ulcerative colitis in difficult-to-treat inflammatory bowel disease: a single-center retrospective study in Japan

Key Points

• To assess the efficacy and safety of mirikizumab as a maintenance therapy for ulcerative colitis in patients with difficult-to-treat inflammatory bowel disease.
• Conducted a single-center retrospective review of patients
• Focused on maintenance therapy with mirikizumab
• Collected and analyzed real-world treatment data
• Demonstrated promising efficacy of mirikizumab in maintaining remission
• Highlighted a favorable safety profile among treated patients
• Provided supporting data for the use of mirikizumab in difficult-to-treat cases